Please enable JavaScript to continue using this application.

Compare $LXEO vs $NWBO | Chartloom

Compare

$LXEO vs $NWBO

Lexeo Therapeutics Inc · Northwest Biotherapeutics Inc

LXEO

Lexeo Therapeutics Inc

NWBO

Northwest Biotherapeutics Inc

Compare $LXEO vs $NWBO

Comparing Lexeo Therapeutics Inc and Northwest Biotherapeutics Inc

LXEOLexeo Therapeutics Inc

NWBONorthwest Biotherapeutics Inc

LXEOLexeo Therapeutics Inc

Market cap

$254M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-66.4%

52W performance

-59.8%

FCF yield

-35.0%

NWBONorthwest Biotherapeutics Inc

Market cap

$258M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

98.6%

YTD performance

-38.4%

52W performance

-36.2%

FCF yield

-19.3%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

LXEO

NWBO

Detailed metrics comparison

LXEO

Lexeo Therapeutics Inc

NWBO

Northwest Biotherapeutics Inc

Market Cap

LXEO$254M

NWBO$258M

Enterprise Value

LXEO$161M

NWBO$309M

Price

LXEO$3.23

NWBO$0.16

P/E Ratio

LXEON/A

NWBON/A

P/S Ratio

LXEO535.16x

NWBO118.73x

EV/Sales

LXEO0.00x

NWBO142.38x

EV/EBITDA

LXEO0.00x

NWBO0.00x

P/B Ratio

LXEO1.23x

NWBO217.71x

P/FCF Ratio

LXEON/A

NWBON/A

EV/FCF

LXEO-1.82x

NWBO-6.22x

PEG Ratio

LXEON/A

NWBON/A

Forward P/E (NTM)

LXEON/A

NWBON/A

Forward P/S (NTM)

LXEON/A

NWBON/A

Revenue (TTM)

LXEO$0

NWBO$2M

Revenue Growth (YoY)

LXEON/A

NWBO98.6%

Forward Rev Growth

LXEO466.0%

NWBO3240.0%

Gross Margin (TTM)

LXEO0.0%

NWBO100.0%

Operating Margin (TTM)

LXEO0.0%

NWBO0.0%

EBITDA Margin (TTM)

LXEO0.0%

NWBO-2190.8%

Net Margin (TTM)

LXEO0.0%

NWBO-1789.4%

FCF Margin (TTM)

LXEON/A

NWBO-2290.3%

Net Income (TTM)

LXEO$-87M

NWBO$-39M

FCF (TTM)

LXEO$-89M

NWBO$-50M

EPS (TTM)

LXEO-$1.02

NWBO-$0.02

ROE (TTM)

LXEO-4185.0%

NWBO-30338.0%

ROA (TTM)

LXEO-3803.0%

NWBO-5634.0%

ROIC (TTM)

LXEO-4169.0%

NWBO-23067.0%

Cash

LXEO$93M

NWBO$595K

Debt

LXEO$584K

NWBO$52M

Net Cash/Debt

LXEO$92M

NWBO$-51M

Current Ratio (TTM)

LXEO13.89x

NWBO0.04x

Quick Ratio (TTM)

LXEO13.49x

NWBO0.01x

Debt/Equity (TTM)

LXEO0.00x

NWBO0.00x

Debt/Assets (TTM)

LXEO0.0%

NWBO0.0%

Interest Coverage (TTM)

LXEON/A

NWBON/A

Net Debt/EBITDA (TTM)

LXEO0.00x

NWBO0.00x

Beta

LXEO1.62

NWBO-0.58

52W Performance

LXEO-59.8%

NWBO-36.2%

YTD Performance

LXEO-66.4%

NWBO-38.4%

% from 52W High

LXEO-70.6%

NWBO-53.7%

% from 52W Low

LXEO8.4%

NWBO13.7%

Asset Turnover (TTM)

LXEO0.00x

NWBO0.03x

FCF Yield (TTM)

LXEO-35.0%

NWBO-19.3%

Earnings Yield (TTM)

LXEO-34.4%

NWBO-15.1%

Dividend Yield (TTM)

LXEON/A

NWBON/A

Rule of 40

LXEO0.0

NWBO-2,191.7

EV/GP/RG

LXEON/A

NWBO0.04

Ticker research

View LXEO research View NWBO research

Metric	LXEO Lexeo Therapeutics Inc	NWBO Northwest Biotherapeutics Inc
Market & Valuation
Market Cap	$254M	$258M
Enterprise Value	$161M	$309M
Price	$3.23	$0.16
P/E Ratio	N/A	N/A
P/S Ratio	535.16x	118.73x
EV/Sales	0.00x	142.38x
EV/EBITDA	0.00x	0.00x
P/B Ratio	1.23x	217.71x
P/FCF Ratio	N/A	N/A
EV/FCF	-1.82x	-6.22x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$2M
Revenue Growth (YoY)	N/A	98.6%
Forward Rev Growth	466.0%	3240.0%
Profitability
Gross Margin (TTM)	0.0%	100.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-2190.8%
Net Margin (TTM)	0.0%	-1789.4%
FCF Margin (TTM)	N/A	-2290.3%
Net Income (TTM)	$-87M	$-39M
FCF (TTM)	$-89M	$-50M
EPS (TTM)	-$1.02	-$0.02
ROE (TTM)	-4185.0%	-30338.0%
ROA (TTM)	-3803.0%	-5634.0%
ROIC (TTM)	-4169.0%	-23067.0%
Financial Health
Cash	$93M	$595K
Debt	$584K	$52M
Net Cash/Debt	$92M	$-51M
Current Ratio (TTM)	13.89x	0.04x
Quick Ratio (TTM)	13.49x	0.01x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.62	-0.58
52W Performance	-59.8%	-36.2%
YTD Performance	-66.4%	-38.4%
% from 52W High	-70.6%	-53.7%
% from 52W Low	8.4%	13.7%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.03x
FCF Yield (TTM)	-35.0%	-19.3%
Earnings Yield (TTM)	-34.4%	-15.1%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-2,191.7
EV/GP/RG	N/A	0.04
Ticker research	View LXEO research	View NWBO research

Valuation

P/S Ratio

NWBO

118.73x

LXEO

535.16x

EV/FCF

NWBO

-6.22x

LXEO

-1.82x

Growth & revenue

Revenue Growth TTM

NWBO

98.6%

Forward Revenue Growth

NWBO

3240.0%

LXEO

466.0%

Profitability & performance

Gross Margin

NWBO

100.0%

LXEO

0.0%

ROE

LXEO

-4185.0%

NWBO

-30338.0%

FCF Yield %

NWBO

-19.3%

LXEO

-35.0%

52-Week Performance

NWBO

-36.2%

LXEO

-59.8%

Detailed metrics comparison

LXEO

Lexeo Therapeutics Inc

NWBO

Northwest Biotherapeutics Inc

Market Cap

LXEO$254M

NWBO$258M

Enterprise Value

LXEO$161M

NWBO$309M

Price

LXEO$3.23

NWBO$0.16

P/E Ratio

LXEON/A

NWBON/A

P/S Ratio

LXEO535.16x

NWBO118.73x

EV/Sales

LXEO0.00x

NWBO142.38x

EV/EBITDA

LXEO0.00x

NWBO0.00x

P/B Ratio

LXEO1.23x

NWBO217.71x

P/FCF Ratio

LXEON/A

NWBON/A

EV/FCF

LXEO-1.82x

NWBO-6.22x

PEG Ratio

LXEON/A

NWBON/A

Forward P/E (NTM)

LXEON/A

NWBON/A

Forward P/S (NTM)

LXEON/A

NWBON/A

Revenue (TTM)

LXEO$0

NWBO$2M

Revenue Growth (YoY)

LXEON/A

NWBO98.6%

Forward Rev Growth

LXEO466.0%

NWBO3240.0%

Gross Margin (TTM)

LXEO0.0%

NWBO100.0%

Operating Margin (TTM)

LXEO0.0%

NWBO0.0%

EBITDA Margin (TTM)

LXEO0.0%

NWBO-2190.8%

Net Margin (TTM)

LXEO0.0%

NWBO-1789.4%

FCF Margin (TTM)

LXEON/A

NWBO-2290.3%

Net Income (TTM)

LXEO$-87M

NWBO$-39M

FCF (TTM)

LXEO$-89M

NWBO$-50M

EPS (TTM)

LXEO-$1.02

NWBO-$0.02

ROE (TTM)

LXEO-4185.0%

NWBO-30338.0%

ROA (TTM)

LXEO-3803.0%

NWBO-5634.0%

ROIC (TTM)

LXEO-4169.0%

NWBO-23067.0%

Cash

LXEO$93M

NWBO$595K

Debt

LXEO$584K

NWBO$52M

Net Cash/Debt

LXEO$92M

NWBO$-51M

Current Ratio (TTM)

LXEO13.89x

NWBO0.04x

Quick Ratio (TTM)

LXEO13.49x

NWBO0.01x

Debt/Equity (TTM)

LXEO0.00x

NWBO0.00x

Debt/Assets (TTM)

LXEO0.0%

NWBO0.0%

Interest Coverage (TTM)

LXEON/A

NWBON/A

Net Debt/EBITDA (TTM)

LXEO0.00x

NWBO0.00x

Beta

LXEO1.62

NWBO-0.58

52W Performance

LXEO-59.8%

NWBO-36.2%

YTD Performance

LXEO-66.4%

NWBO-38.4%

% from 52W High

LXEO-70.6%

NWBO-53.7%

% from 52W Low

LXEO8.4%

NWBO13.7%

Asset Turnover (TTM)

LXEO0.00x

NWBO0.03x

FCF Yield (TTM)

LXEO-35.0%

NWBO-19.3%

Earnings Yield (TTM)

LXEO-34.4%

NWBO-15.1%

Dividend Yield (TTM)

LXEON/A

NWBON/A

Rule of 40

LXEO0.0

NWBO-2,191.7

EV/GP/RG

LXEON/A

NWBO0.04

Ticker research

View LXEO research View NWBO research

Metric	LXEO Lexeo Therapeutics Inc	NWBO Northwest Biotherapeutics Inc
Market & Valuation
Market Cap	$254M	$258M
Enterprise Value	$161M	$309M
Price	$3.23	$0.16
P/E Ratio	N/A	N/A
P/S Ratio	535.16x	118.73x
EV/Sales	0.00x	142.38x
EV/EBITDA	0.00x	0.00x
P/B Ratio	1.23x	217.71x
P/FCF Ratio	N/A	N/A
EV/FCF	-1.82x	-6.22x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$2M
Revenue Growth (YoY)	N/A	98.6%
Forward Rev Growth	466.0%	3240.0%
Profitability
Gross Margin (TTM)	0.0%	100.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-2190.8%
Net Margin (TTM)	0.0%	-1789.4%
FCF Margin (TTM)	N/A	-2290.3%
Net Income (TTM)	$-87M	$-39M
FCF (TTM)	$-89M	$-50M
EPS (TTM)	-$1.02	-$0.02
ROE (TTM)	-4185.0%	-30338.0%
ROA (TTM)	-3803.0%	-5634.0%
ROIC (TTM)	-4169.0%	-23067.0%
Financial Health
Cash	$93M	$595K
Debt	$584K	$52M
Net Cash/Debt	$92M	$-51M
Current Ratio (TTM)	13.89x	0.04x
Quick Ratio (TTM)	13.49x	0.01x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.62	-0.58
52W Performance	-59.8%	-36.2%
YTD Performance	-66.4%	-38.4%
% from 52W High	-70.6%	-53.7%
% from 52W Low	8.4%	13.7%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.03x
FCF Yield (TTM)	-35.0%	-19.3%
Earnings Yield (TTM)	-34.4%	-15.1%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-2,191.7
EV/GP/RG	N/A	0.04
Ticker research	View LXEO research	View NWBO research